what it means for the clinical management and treatment of fatty liver, and the need for new MAFLD disease models. The conversation was led by Hirokazu Takahashi, a physician specializing in ...
The patient, who suffered from advanced liver cancer was enrolled in the former Can-Fite Phase II study, continue to be treated with Namodenoson, and has now an overall survival of 8 years, with ...
The once 55-kg mother gained 10kg as treatment included steroids. “As I gained weight, my liver too got enlarged, and I was medically found to have another condition called fatty liver disease,’’ said ...